Author: Pershadsingh Harrihar A
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.16, Iss.3, 2007-03, pp. : 291-302
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
In animal experiments, the potent antioxidant and free radical scavenger α-lipoic acid has been shown to cause weight loss, ameliorate insulin resistance and atherogenic dyslipidemia, as well as to lower blood pressure, all of these being components of the metabolic syndrome. Recent investigations on its mechanisms of action indicate that α-lipoic acid can affect central and peripheral modulation of 5′-AMP-activated protein kinase, activate PPAR-α and PPAR-&ggr;, modulate PPAR-regulated genes and upregulate the expression of PPAR-&ggr; mRNA and protein in cardiac tissue and aorta smooth muscle. To a large extent, these findings can explain the observed beneficial metabolic effects of α-lipoic acid, supporting its potential application as a therapeutic agent for the treatment of the metabolic syndrome.
Related content
α-Lipoic acid, an anti-obesity agent?
Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. :
-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design, Vol. 16, Iss. 7, 2010-03 ,pp. :
By El Midaoui Adil Lungu Calin Wang Hui Wu Lingyun Robillard Caroline DeBlois Denis Couture Réjean
Canadian Journal of Physiology and Pharmacology, Vol. 89, Iss. 10, 2011-10 ,pp. :